COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

ICCVAM Logo

ICCVAM Biennial Report 2018-2019

ICCVAM Biennial Report 2018-2019
Menu
https://ntp.niehs.nih.gov/go/884588

ICCVAM Public Forums

ICCVAM held two public forum meetings in 2018 and 2019. These annual meetings provide an opportunity for public interaction with representatives from ICCVAM member agencies.

ICCVAM held its fifth public forum on May 24, 2018, at NIH in Bethesda, Maryland. This meeting was attended by about 100 individuals in person and remotely, who heard presentations by ICCVAM members on current activities related to the development and validation of alternative test methods and approaches. Seven ICCVAM member agencies provided updates on activities. Other presentations described FDA and EPA strategic plans to promote the use of non-animal methods and the updated Tox21 strategic plan and goals for the program’s next five years. A major focus of this meeting was implementation of the Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States. Commenters offered suggestions on specific actions that should be taken to advance the goals of the Strategic Roadmap and encouraged agencies that have been less active in ICCVAM activities to take a greater role.

The 2019 public forum was held on May 23 at NIH in Bethesda. About 40 public participants and over 200 webcast viewers heard presentations by ICCVAM members representing eight U.S. agencies on current activities related to the development and validation of alternative test methods and approaches, many of which addressed goals of the Strategic Roadmap. A key focus was progress made towards reduction and replacement of animal use for acute toxicity tests required by regulatory agencies: acute systemic toxicityskin and eye irritation, and skin sensitization testing. Public comments submitted to the meeting praised specific actions agencies had taken to advance the Strategic Roadmap goals and suggested additional activities that could support further progress.

Tags: